Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Refractory Plasma Cell MyelomaRecurrent Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 77
- Registration Number
- NCT00966693
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Drug: DocetaxelDrug: CarboplatinDrug: DexamethasoneBiological: EBV-specific cytotoxic T lymphocytesBiological: G-CSF or Peg-GCSF
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT00953420
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)
- Conditions
- Chemotherapy-induced Nausea and Vomiting (CINV)
- Interventions
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 421
- Registration Number
- NCT00952341
To Evaluate the Efficacy and Tolerability of the Use of Vitatonus Dexa Compared to Dexamethasone in Patients With Neuralgia of Various Origins
- First Posted Date
- 2009-07-23
- Last Posted Date
- 2009-07-24
- Lead Sponsor
- Bunker Industria Farmaceutica Ltda.
- Target Recruit Count
- 104
- Registration Number
- NCT00944502
- Locations
- 🇧🇷
Faculdade de Medicina do ABC, Santo André, São Paulo, Brazil
Comparison of Oral Dexamethasone Doses in Asthma Exacerbation
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2009-07-20
- Lead Sponsor
- Rady Children's Hospital, San Diego
- Target Recruit Count
- 125
- Registration Number
- NCT00942201
- Locations
- 🇺🇸
Rady Children's Hospital, San Diego, California, United States
A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 25
- Registration Number
- NCT00928486
- Locations
- 🇯🇵
Nagoya Medical Center, Nagoya-city, Aichi, Japan
🇯🇵Niigata Cancer Center Hospital, Niigata-city, Niigata, Japan
🇯🇵Keio University Hospital, Tokyo, Japan
Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
- Conditions
- Relapsed Acute Lymphoblastic LeukemiaAllergy to PEG e.Coli AsparaginaseAllergy to Native e.Coli Asparaginase
- Interventions
- Drug: ErwinaseDrug: VincristineDrug: DexamethasoneDrug: DoxorubicinDrug: CytarabineDrug: MethotrexateDrug: Triple Intrathecal TherapyDrug: Dexrazoxane
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Target Recruit Count
- 1
- Registration Number
- NCT00928200
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: FDG-PETDrug: PemetrexedDrug: SirolimusDietary Supplement: Vitamin B12Dietary Supplement: Folic acid tabletsDrug: Dexamethasone tablets
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00923273
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: bleomycin sulfateDrug: ABVD regimenDrug: cisplatinDrug: carmustineDrug: cytarabineDrug: dacarbazineDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: etoposideDrug: gemcitabine hydrochlorideDrug: vincristine sulfateDrug: ifosfamideDrug: vindesineDrug: melphalanDrug: methylprednisoloneDrug: mitoguazoneDrug: vinorelbine tartrateProcedure: allogeneic hematopoietic stem cell transplantationProcedure: autologous hematopoietic stem cell transplantation
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 442
- Registration Number
- NCT00920153
- Locations
- 🇫🇷
FILO French Innovative Leukemia Organization, Tours Cedex, France
A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2015-09-02
- Lead Sponsor
- King's College Hospital NHS Trust
- Target Recruit Count
- 32
- Registration Number
- NCT00915408
- Locations
- 🇬🇧
King's College Hospital NHS Foundation Trust, London, United Kingdom
🇬🇧Royal Marsden NHS Foundation Trust, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.